Agios Pharmaceuticals (NASDAQ:AGIO) reported Q4 2017 earnings this Morning, coming in at ($1.81) per share, missing Wall Street’s estimates of ($1.65) per Share. Revenue for the quarter came in at $9.80 million beating analyst estimates of $12.65 million Recent Insider Trading for Agios Pharmaceuticals (NASDAQ:AGIO)
- On 2/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $76.04 per share and the total transaction amounting to $228,120.00.
- On 2/1/2018 Christopher Bowden, Insider, sold 2,000 with an average share price of $78.75 per share and the total transaction amounting to $157,500.00.
- On 2/1/2018 David P Schenkein, CEO, sold 13,000 with an average share price of $78.75 per share and the total transaction amounting to $1,023,750.00.
- On 1/26/2018 David P Schenkein, CEO, sold 23,572 with an average share price of $81.09 per share and the total transaction amounting to $1,911,453.48.
- On 1/24/2018 David P Schenkein, CEO, sold 46,408 with an average share price of $80.01 per share and the total transaction amounting to $3,713,104.08.
- On 1/23/2018 Corp /De/ Celgene, Major Shareholder, bought 851,154 with an average share price of $67.00 per share and the total transaction amounting to $57,027,318.00.
Recent Trading for Agios Pharmaceuticals (NASDAQ:AGIO) Shares of Agios Pharmaceuticals closed the previous trading session at 76.06 down -0.47 0.61% with 590 shares trading hands.